Priothera Fundraising

THM Capital Advisory supports Priothera in the finalization of the financing of the first instalment of its Series B.
‍

Activity

Priothera is a European biotech in the advanced phase of development in hemato-oncology.

The company is developing mocravimod, an immunomodulator currently in clinical Phase III, for the treatment of acute myeloid leukemia (AML), with the aim of improving patients' relapse-free survival.
‍

Objectives

Finalize a first Series B (B1) installment of €18.6 million, including €4 million raised by THM Capital Advisory from family offices and business angels, alongside existing investors and new co-leads.

Fund the continuation of the clinical development of mocravimod and prepare the next stages of fundraising (additional Series B instalment).
‍

Investors

Historical investors (Fountain Healthcare Partners, HealthCap, Earlybird) and new co-lead investors (4See Ventures, Sprim Global Investments), as well as family offices and business angels.